Trials / Terminated
TerminatedNCT02663908
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix (Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist)
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 545 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in subjects with prostate cancer and cardiovascular disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Degarelix | |
| DRUG | Leuprolide |
Timeline
- Start date
- 2016-04-19
- Primary completion
- 2021-03-29
- Completion
- 2021-03-29
- First posted
- 2016-01-26
- Last updated
- 2022-06-29
- Results posted
- 2022-06-29
Locations
133 sites across 12 countries: United States, Canada, Czechia, Finland, France, Germany, Greece, Poland, Russia, Slovakia, South Africa, United Kingdom
Source: ClinicalTrials.gov record NCT02663908. Inclusion in this directory is not an endorsement.